ENTITY
Hangzhou Tigermed Consulting (A)

Hangzhou Tigermed Consulting (A) (300347 CH)

96
Analysis
Health CareChina
Hangzhou Tigermed Consulting Company Limited provides professional clinical research services for domestic and foreign pharmaceutical and health-related research and development. The Company's main services include clinical trial technology services, data management, and statistical analysis.
more
Refresh
03 Jan 2019 10:23

Discover SZ/​SH Connect: Foreigners Were Buying Industries and Financials in December

In our Discover SZ/SH Connect series, we aim to help our investors understand the flow of northbound trades via the Shanghai Connect and Shenzhen...

Logo
557 Views
Share
bearishWuXi AppTec
11 Dec 2018 19:57

WuXi AppTec IPO Valuation: Bull/​Bear Case DCF Scenarios

WuXi AppTec Co. Ltd. (WUXI HK) is a leading global pharmaceutical R&D outsourcing service provider and the largest in Asia by revenue in 2017....

Logo
511 Views
Share
07 Dec 2018 15:32

Ascentage Pharma (亚盛医药) IPO: Too Early for an IPO

Ascentage Pharma, a China-based biotech company, filed an application to list on the Hong Kong Stock Exchange. In this insight, we will cover the...

Logo
1k Views
Share
bullishWuXi AppTec
28 Nov 2018 11:42

WuXi Apptec (药明康德) IPO:Upside at Middle and Low End

Wuxi Apptec launched book building today with a price range of HKD 64.10 to HKD 71.50, planning to raise USD 954 million to USD 1,064 million. In...

Logo
728 Views
Share
bearishWuXi AppTec
28 Nov 2018 05:57

WuXi AppTech IPO Update: Figuring Out the Right AH Premium

WuXi AppTec Co. Ltd. (WUXI HK) is a leading global pharmaceutical R&D outsourcing service provider and the largest in Asia by revenue in 2017....

Logo
708 Views
Share
x